Aurobindo Pharma today said it has received the US health regulator's approval to sell its generic Levofloxacin injection, used to treat infections, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Levofloxacin injection in strength of 25mg/ml, packaged in 500mg/20ml and 750mg/30ml single-use vials, Aurobindo Pharma said in a statement.
The company's product is generic equivalent of Janssen Pharmaceuticals Inc's Levaquin injection and is indicated for the treatment of adults with mild, moderate, and severe infections, it added.
Aurobindo now has a total of 175 abbreviated new drug (ANDA) approvals from the USFDA, the company said.
Shares of Aurobindo were trading at Rs 187.90 on the BSE in late afternoon trade, up 1.76 per cent from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app